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Diet is a key lifestyle factor that can have long-term effects on ocular health. This Special Issue
of Nutrients entitled ‘Nutrition and Eye Health’ contains 12 articles, including reviews and primary
research studies, that report on a diverse range of topics relating to the role of nutrition in maintaining
eye health, and the potential use of nutritional interventions for preventing or treating ocular disease.
Collectively, these papers span a spectrum of ocular conditions, including corneal angiogenesis [1],
cataract [2–4], diabetic retinopathy [5], age-related macular degeneration (AMD) [6,7], and experimental
models of retinal disease [8–10]. In addition, clinically focussed papers report on the validation of
a novel food frequency questionnaire for assessing long-chain omega-3 fatty acid intake in eye care
practice [11], and evidence relating to the applicability of saffron for treating ocular disease [12].
Globally, approximately 250 million people suffer from varying degrees of vision loss [13]. Leading
causes include several eye conditions considered in this Special Issue, such as cataract, AMD, glaucoma,
and diabetic retinopathy. These conditions disproportionately affect older adults, and with an ageing
population the number of affected individuals is predicted to increase exponentially [13]. Whilst the
aetiology of age-related eye disease is complex and multifactorial, oxidative stress has been implicated
as a common causative mechanism. The eye is particularly susceptible to oxidative stress as a result
of its high oxygen consumption, high concentration of polyunsaturated fatty acids and cumulative
exposure to high-energy visible light. This combination of factors leads to the generation of reactive
oxygen species that can trigger oxidative damage to ocular tissues. Consequently, there has been
significant research interest in the role of dietary antioxidants and the potential therapeutic benefits
of antioxidant vitamin and mineral supplements as a simple and cost-effective strategy for disease
prevention and/or control [14–17].
AMD is characterised by degenerative changes within the macula, the central area of the retina
that is responsible for high-resolution vision, in people aged 55 years or older. AMD is a leading cause
of severe vision impairment in European-derived populations. In the UK, the disease is responsible for
over 50% of certifiable vision loss [18]. Although epidemiological studies have provided reasonably
consistent evidence that diet is an important modifiable risk factor for AMD [19], concerns have been
raised about the validity of findings from non-interventional studies due to the potential influence of
confounding factors. For example, people with a particular dietary pattern may differ in other ways
(e.g., the amount of exercise they undertake, their daily level of light exposure) and it is not typically
possible to control for these differences [20].
In terms of primary research studies, the highest quality evidence to evaluate the efficacy and safety
of therapeutic interventions derives from randomised controlled trials (RCTs). In RCTs, participants
are randomly allocated to receive either the intervention or a comparator (typically placebo or no
intervention), which minimises the potential for bias in the intervention assignment [21]. There
is evidence from RCTs that prophylactic antioxidant vitamin or mineral supplementation does not
prevent the development of AMD [22]. Five large RCTs have compared supplements containing
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vitamin E, beta-carotene, vitamin C, or antioxidant vitamin combinations with placebo in people from
the general population. These trials randomised more than 75,000 people and followed their clinical
outcomes between 4 to 10 years. People taking these supplements were found to have a similar risk of
developing AMD to those not taking the supplements [22].
Other RCTs have investigated whether high-dose antioxidant vitamin and mineral supplements
can slow the progression of AMD [23]. Most of these trials recruited small numbers of participants and
were of relatively short duration, ranging from 9 months to 6 years. However, one large, multi-centre
RCT conducted in the USA, the Age-Related Eye Disease Study (AREDS), randomised 3640 individuals
with AMD to take supplement formulations containing combinations of vitamin C, E, beta-carotene,
zinc, and copper, or a placebo, each day. A major conclusion from the AREDS was that daily, long-term
supplementation with vitamin C (500 mg), vitamin E (400 international units (IU)), beta-carotene
(15 mg), zinc (80 mg, as zinc oxide), and copper (2 mg, as cupric oxide) reduced the relative risk of
progression to late-stage AMD from 28% (observed with placebo) to 20% at 5 years, in people with at
least intermediate AMD. This means that for people with intermediate AMD, who are at the highest risk
of progression to late AMD, 80 fewer cases would progress for every 1000 people taking the supplement.
However, safety concerns were raised regarding high-dose supplementation of the carotenoid used
in the original AREDS supplement, beta-carotene, in people who smoke [24]. In a follow-up study
by the AREDS investigators, AREDS2, current smokers or those who had ceased smoking for less
than 12 months before enrolment were not eligible to receive beta-carotene supplementation [25].
The primary analysis in AREDS2 demonstrated that adding lutein and zeaxanthin and/or omega-3 fatty
acids to the AREDS formula was not associated with a significant reduction in the risk of progression
to late-stage AMD compared with the original supplement. Lutein and zeaxanthin are carotenoids that
are major components of macula pigment. They are proposed to have a protective role in the retina
through their antioxidant properties and ability to act as a filter for blue light [26]. Exploratory analyses
from AREDS2 suggested that lutein and zeaxanthin may be of value for reducing AMD progression
when given without beta-carotene, but that more research was required to test this hypothesis [27].
Cataract is defined as any visible opacity within the otherwise clear crystalline lens of the eye.
Cataract can be further classified as cortical, nuclear, or posterior sub-capsular, depending on the
anatomical location of the opacity. Globally, over 60 million people are visually impaired due to cataract,
however cataract-associated blindness shows significant geographical variation, accounting for less
than 22% of blindness in high-income countries compared to more than 44% in South East Asia [13].
Age is the most significant risk factor for cataractogenesis. As the lens ages, conformational changes to
lens proteins occur with subsequent aggregation, leading to a progressive loss of transparency and
associated vision loss [28]. Oxidation reactions within the lens are thought to be a key factor in this
process and there has been a significant amount of research on the role of antioxidant nutrients for
preventing or slowing the progression of cataract [29]. Observational data suggest that the risk of
cataracts can be reduced by a diet that contains optimal levels of vitamins C and E, the carotenoids
lutein and zeaxanthin, and the daily use of multivitamin supplements [29]. However, RCTs that have
compared antioxidant vitamin supplements (beta-carotene, vitamins C and E) to an inactive placebo or
no supplement have been unable to detect any effect on the incidence or progression of cataract [30].
The lack of efficacy in these relatively short-term trials could suggest that a longer-term intake or a
particular combination of antioxidants is required. A study of baseline factors that predicted cataract
in the AREDS cohort found that the use of multivitamins supplements reduced the risk of developing
nuclear cataracts over an approximate 10 year follow-up period [31].
In conclusion, age-related eye diseases, including cataract and AMD, are of global public health
concern. Acquired vision loss associated with these conditions can be devastating to the individual
through its detrimental impact on quality of life, and also impart substantial societal burden. Although
the pathogenesis of these conditions is not fully understood, there is increasing evidence that their impact
can, to some extent, be mitigated by targeting modifiable risk factors. Since diet and nutrition have
been linked with the most common diseases affecting the elderly, dietary modification and nutritional
Nutrients 2019, 11, 2123 3 of 4
supplementation for the prevention and treatment of these diseases has attracted a considerable
amount of scientific attention. As evidenced by the quality and diversity of the contributions in this
Special Issue, the role of nutrition in eye health remains a highly topical area, with scope for future
research to enhance our understanding of the role of nutritional strategies for optimising eye health.
Author Contributions: J.G.L. and L.E.D. wrote the editorial.
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